Tripartite motif-containing protein 50 suppresses triple-negative breast cancer progression by regulating the epithelial-mesenchymal transition.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101137842 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1555-8576 (Electronic) Linking ISSN: 15384047 NLM ISO Abbreviation: Cancer Biol Ther Subsets: MEDLINE
    • Publication Information:
      Publication: 2015- : Philadelphia, PA : Taylor & Francis
      Original Publication: Georgetown, TX : Landes Bioscience, c2002-
    • Subject Terms:
      Epithelial-Mesenchymal Transition* ; Triple Negative Breast Neoplasms*/pathology ; Triple Negative Breast Neoplasms*/metabolism ; Triple Negative Breast Neoplasms*/genetics ; Tripartite Motif Proteins*/metabolism ; Tripartite Motif Proteins*/genetics ; Cell Proliferation* ; Ubiquitin-Protein Ligases*/metabolism ; Ubiquitin-Protein Ligases*/genetics ; Disease Progression* ; Cell Movement*; Humans ; Female ; Cell Line, Tumor ; Apoptosis ; Gene Expression Regulation, Neoplastic ; Snail Family Transcription Factors/metabolism ; Snail Family Transcription Factors/genetics
    • Abstract:
      Background and Objectives: Tripartite motif-containing protein 50 (TRIM50) is a recently discovered E3 ubiquitin ligase that participates in tumor progression. TRIM50 is overexpressed in many cancers, although few studies focused on TRIM50's role in breast cancer.
      Methods: We overexpressed TRIM50 in triple-negative breast cancer cell lines using plasmid and found that TRIM50 upregulation markedly reduced breast cancer cell proliferation, clone formation, and migration, as well as promoted breast cancer cell apoptosis. Western blotting revealed that accumulated TRIM50 resulted in both mRNA and protein depletion of SNAI1, and partially attenuated the epithelial-mesenchymal transition (EMT) induced by SNAI1.
      Results: In this study, we demonstrate that TRIM50 is downregulated in human breast cancer and that its overexpression closely correlates with diminished invasion capacity in breast cancer, suggesting that TRIM50 may serve as a diagnostic marker and therapeutic target.
      Conclusion: TRIM50 plays a key role in breast cancer proliferation and potentially serves as a prognostic and therapeutic target.
    • References:
      Epigenomics. 2019 Aug;11(10):1163-1176. (PMID: 31337246)
      Clin Transl Oncol. 2022 Mar;24(3):460-470. (PMID: 34643877)
      Drug Resist Updat. 2024 Mar;73:101063. (PMID: 38335844)
      Int J Mol Sci. 2023 Aug 19;24(16):. (PMID: 37629161)
      PLoS One. 2012;7(7):e40440. (PMID: 22792322)
      Research (Wash D C). 2023 Dec 15;6:0289. (PMID: 38111678)
      Oncogene. 2018 Jul;37(30):4137-4150. (PMID: 29706651)
      Cell Mol Life Sci. 2012 Oct;69(20):3429-56. (PMID: 22945800)
      Annu Rev Biochem. 2017 Jun 20;86:129-157. (PMID: 28375744)
      Biosci Rep. 2021 Aug 27;41(8):. (PMID: 34387660)
      Biomolecules. 2021 Oct 14;11(10):. (PMID: 34680146)
      Clin Cancer Res. 2005 Sep 1;11(17):6148-54. (PMID: 16144914)
      Annu Rev Biochem. 2012;81:203-29. (PMID: 22524316)
      CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
      Front Oncol. 2021 Sep 09;11:695740. (PMID: 34568024)
      Nat Commun. 2023 Apr 15;14(1):2160. (PMID: 37061529)
      Mol Cancer Res. 2023 Oct 2;21(10):1107-1119. (PMID: 37409971)
      Neoplasia. 2014 May;16(5):390-402. (PMID: 25016594)
      Biochim Biophys Acta Mol Cell Res. 2018 Jun;1865(6):908-919. (PMID: 29604308)
      Gastroenterology. 2006 Sep;131(3):830-40. (PMID: 16952552)
      Genome Med. 2018 Dec 3;10(1):94. (PMID: 30501643)
      Genes Dis. 2022 Feb 18;10(3):848-863. (PMID: 37396527)
      Nature. 2002 Jun 20;417(6891):871-5. (PMID: 12075357)
      Biochem Biophys Res Commun. 2023 Jan 15;640:26-31. (PMID: 36495607)
      Nat Rev Cancer. 2013 Feb;13(2):97-110. (PMID: 23344542)
      Hum Genomics. 2022 Dec 2;16(1):65. (PMID: 36461099)
      Chin Med J (Engl). 2022 Feb 9;135(5):584-590. (PMID: 35143424)
      Cells. 2019 May 27;8(5):. (PMID: 31137886)
      J Gen Virol. 2019 Dec;100(12):1641-1662. (PMID: 31661051)
      Clin Breast Cancer. 2021 Dec;21(6):509-520. (PMID: 34629314)
      Life Sci. 2021 Mar 1;268:118985. (PMID: 33412211)
      PLoS Biol. 2018 Nov 8;16(11):e3000051. (PMID: 30408026)
      J Clin Invest. 2014 Jan;124(1):398-412. (PMID: 24316975)
      J Oncol. 2022 Aug 22;2022:5936753. (PMID: 36046365)
      PLoS Comput Biol. 2018 Aug 10;14(8):e1006349. (PMID: 30096183)
      Biochim Biophys Acta Mol Cell Res. 2019 Sep;1866(9):1412-1420. (PMID: 31176697)
      BMC Genomics. 2006 Apr 27;7:96. (PMID: 16643655)
      Cell Death Dis. 2018 May 22;9(6):608. (PMID: 29789583)
    • Contributed Indexing:
      Keywords: EMT; TRIM50; biomarker; triple-negative breast cancer
    • Accession Number:
      0 (Tripartite Motif Proteins)
      EC 2.3.2.27 (Ubiquitin-Protein Ligases)
      0 (Snail Family Transcription Factors)
      0 (SNAI1 protein, human)
    • Publication Date:
      Date Created: 20241114 Date Completed: 20241114 Latest Revision: 20241120
    • Publication Date:
      20241120
    • Accession Number:
      PMC11572070
    • Accession Number:
      10.1080/15384047.2024.2427410
    • Accession Number:
      39538371